Search Results

The Foundation for the National Institutes of Health will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, AbbVie, and Robert and Sarah Newcomb.

The Foundation for the National Institutes of Health announces that Love Collins, III, has joined as Vice President of Advancement.

The Foundation for the National Institutes of Health announces two additions to the FNIH Board of Directors: James W. Down, former Vice Chairman of Mercer Management Consulting, and Perry Steiner, Chairman and CEO of Xactus.

The Foundation for the National Institutes of Health announces the launch of a public-private partnership to build the largest data source for amyotrophic lateral sclerosis and expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for people living with the disease.

Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.

Andelyn Biosciences, Inc. has been selected to manufacture adeno-associated vectors therapies in its suspension platform for several programs under the Foundation for the National Institutes of Health Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium.

The Foundation for the National Institutes of Health announces two new additions to the FNIH Board of Directors, Nina Kjellson, General Partner at Canaan, and Charles Reinhart III, Chief Financial Officer at Pacira BioSciences, Inc.